Oncology

Back to articles

In ovarian cancer, bevacizumab plus chemotherapy decreases progression

KEY POINT

Added to standard chemotherapy, bevacizumab (Avastin—Genentech), an angiogenic inhibitor, improved progression-free survival in women with ovarian cancer, according to results of two large international trials.

SOURCES

Burger RA et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473–83.

Perren TJ et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–96.